Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd.
2026 · Licensing/Option · $1.3B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
65
Largely worked — most objectives met.
On June 1, 2026, Eli Lilly licensed global rights (outside Korea) to sonefpeglutide, Hanmi Pharmaceutical's long-acting GLP-2 receptor agonist, in a deal worth up to approximately $1.26 billion. Hanmi receives $75 million upfront and is eligible for up to $1.185 billion in clinical, regulatory and commercial milestone payments plus tiered royalties. The lead indication is short bowel syndrome, a rare malabsorption disorder; Hanmi has an ongoing U.S. Phase 2 study (DOLPHINS-2), and Lilly will explore additional gastrointestinal indications. The deal extends Lilly's gastrointestinal and incretin-biology franchise.